Abstract
Growing evidence suggests that abnormal synaptic plasticity of cortical neurons underlies levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). Spine morphology reflects synaptic plasticity resulting from glutamatergic transmission. We previously reported that enlargement of the dendritic spines of intratelencephalic-type (IT) neurons in the primary motor cortex (M1) is linked to the development of LID. However, the relevance of another M1 neuron type, pyramidal-tract (PT) neurons, to LID remains unknown. We examined the morphological changes of the dendritic spines of M1 PT neurons in a rat model of LID. We quantified the density and size of these spines in 6-hydroxydopamine-lesioned rats (a model of PD), 6-hydroxydopamine-lesioned rats chronically treated with levodopa (a model of LID), and control rats chronically treated with levodopa. Dopaminergic denervation alone had no effect on spine density and head area. However, the LID model showed significant increases in the density and spine head area and the development of dyskinetic movements. In contrast, levodopa treatment of normal rats increased spine density alone. Although, chronic levodopa treatment increases PT neuron spine density, with or without dopaminergic denervation, enlargement of PT neuron spines appears to be a specific feature of LID. This finding suggests that PT neurons become hyperexcited in the LID model, in parallel with the enlargement of spines. Thus, spine enlargement, and the resultant hyperexcitability of PT pyramidal neurons, in the M1 cortex might contribute to abnormal cortical neuronal plasticity in LID.
Introduction
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain, resulting in bradykinesia, muscular rigidity, rest tremor, and postural instability (Gibb and Lees, ). The most effective treatment for PD is oral administration of the dopamine precursor, L-3,4-dihydroxyphenylalanine (levodopa) (Olanow et al., ). However, long-term treatment with levodopa induces a variety of abnormal involuntary movements, termed levodopa-induced dyskinesia (LID), which represent a major treatment limitation and reduce the quality of life of PD patients (Olanow et al., ).
The emergence of these abnormal involuntary movements is associated with altered corticostriatal synaptic plasticity (Picconi et al., ). Electrophysiological recordings performed in corticostriatal slices of 6-hydroxydopamine (6-OHDA) lesioned rats with LID have shown that depotentiation at corticostriatal synapses to direct pathway striatal projection neurons (dSPN) is lost after the induction of long-term potentiation (LTP) (Shen et al., ). Depotentiation reverses synaptic strength from the potentiated state to pre-LTP levels, which is implicated in the mechanisms of physiological “forgetting” (Picconi et al., ). Consequently, the absence of depotentiation may result in the storage of unessential motor information, suggesting a key neurophysiological feature of LID (Picconi et al., ). Synapse strength can be determined by alteration of spine volume, or enlargement or shrinkage of spines (Kasai et al., ). Indeed, in a rat model of LID, we showed that dSPN dendritic spines became enlarged, suggesting supersensitivity of the corticostriatal excitatory synapses of dSPNs (Nishijima et al., ).
Dopaminergic signaling within the primary motor cortex (M1) is necessary for normal motor skill learning and synaptic plasticity (Molina-Luna et al., ). Dopaminergic projections to M1 arise from the ventral tegmental area (Hosp et al., ), in which neurons are also lost in PD patients (Uhl et al., ). Thus, progressive degeneration of dopaminergic neurons in the ventral tegmental area leads to decreased endogenous dopamine in the cortex, which affects synaptic plasticity in the M1 (Huang et al., ). In human studies, M1 plasticity is investigated using motor-evoked potential amplitudes elicited by transcranial magnetic stimulation (Huang et al., ). Using this method, PD patients with LID exhibit a lack of depotentiation-like cortical plasticity (Huang et al., ). This suggests that unessential motor information accounting for LID is stored in both in the striatum and the M1 (Picconi et al., ; Huang et al., ).
In rodents, corticostriatal neurons in the motor cortex are categorized into two main types: intratelencephalic (IT) and pyramidal tract (PT) neurons (Reiner et al., ). It has been demonstrated that IT neurons preferentially innervate dSPNs in the ipsilateral and contralateral striatum, whereas PT neurons preferentially innervate SPNs of the indirect pathway (iSPN) in the ipsilateral striatum, and send axons to the brainstem via the pyramidal tract (Reiner et al., ). It has been reported that dSPNs appear to play an important role in the development of LID (Picconi et al., ; Shen et al., ). In a previous study, we found enlargement of IT neuron spines in a LID model rat and proposed that IT neurons in the M1 may store abnormal information resulting in LID (Ueno et al., ). Furthermore, IT neurons in the M1 of the LID rat model displayed increased amplitudes of miniature excitatory postsynaptic currents (Ueno et al., ). These data suggest that IT neurons in dyskinesia-primed animals acquire supersensitivity to excitatory stimuli (Ueno et al., ).
However, it has been demonstrated that dSPNs and iSPNs are innervated by both PT and IT neurons (Kress et al., ; Deng et al., ). Thus, the preferential innervation from IT and PT neurons to SPNs remains controversial (Deng et al., ). Thus, it is conceivable that PT neurons also play an important role in the development of LID. Therefore, we investigated the density and size of PT neuron spines in the M1 in rat models of PD and LID.
Materials and methods
Experimental animals
Male Wistar rats (Japan Clea Co. Ltd., Tokyo, Japan) were housed in a temperature-controlled room (~25°C) with a 12-h day/night cycle, with free access to food and water. This study was conducted in accordance with the guidelines for animal research issued by the Physiological Society of Japan and by Hirosaki University School of Medicine with the approval of Hirosaki University Animal Experimentation Committee.
Creation of rat models
We prepared eight 6-OHDA-lesioned hemiparkinsonian rats (PD model), eight 6-OHDA-lesioned hemiparkinsonian rats with chronic levodopa treatment (LID model), eight control rats with chronic levodopa treatment (levodopa-treated control: LTC model), and nine control rats with saline treatment (Control), as previously described (Ueno et al., ; Figure 1).
Figure 1
6-OHDA (8 mg/4 mL in saline with 0.01% ascorbic acid) (Sigma, San Diego, CA, USA) (PD and LID models) or saline (LTC and Control) was injected into the medial forebrain bundle (4.5 mm posterior to bregma, 1.2 mm lateral to the sagittal suture, and 8.5 mm ventral to the dural surface) in the right hemisphere of 10-week-old rats anesthetized with sodium pentobarbital (Nembutal, 50 mg/kg body weight intraperitoneally; Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan). Apomorphine (Sigma) was administered to evaluate dopaminergic denervation at 12 weeks of age. We previously reported nearly complete dopaminergic denervation in the striatum and M1 with this technique (Maeda et al., ; Ueno et al., ; Figure 1).
During the 4–6 weeks after the apomorphine test, both 6-OHDA-lesioned rats with dopaminergic denervation and sham-operated rats received 50 mg/kg levodopa methyl ester (Sigma) with 12.5 mg/kg benserazide (Sigma) (LID model and LTC models, respectively) or saline (PD model and Control models, respectively), twice daily (morning and evening) for 14 consecutive days (Figure 1). To evaluate the effects of levodopa, we measured abnormal involuntary movement (AIM) scores (Cenci and Lundblad, ) on days 1, 4, and 11 (Figure 1). The AIM score is considered comparable to LID assessments in patients with PD (Cenci and Lundblad, ). We observed and scored the rats every 20 min during the 2-h period following levodopa injection. We assessed and summed the scores for the three AIM subtypes (limb, axial, and orolingual) (Cenci and Lundblad, ).
Dendritic spine morphology
We used eight PD models, eight LID models, nine LTC models, and eight controls at 16–18 weeks of age (Figure 1). Our basic method has previously been described in detail (Ueno et al., ). To selectively label the cell bodies of PT neurons in the right M1, we stereotactically injected a retrograde tracer, Fast Blue (Polysciences, Inc., Warrington, PA, USA), over a 1-min period into the right pontine pyramidal tract (9.6 mm posterior to bregma, 0.5 mm lateral to the sagittal suture, and 10.7 mm ventral to the dural surface) on day 11 of drug treatment (Paxinos and Watson, ; Reiner et al., ) (Figure 1). Four days later, the rats were deeply anesthetized with sodium pentobarbital (Nembutal, >75 mg/kg intraperitoneally), intracardially perfused with 4% paraformaldehyde at 12 h after the last levodopa or saline treatment, and the brains then removed.
Serial 250-μm-thick coronal sections were cut through the M1, and Lucifer Yellow (Sigma) was injected into cell bodies of Fast Blue-labeled neurons in the right M1 under ultraviolet excitation (380–420 nm) with continuous current (up to 100 nA). Neurons were filled with Lucifer Yellow until their dendritic spines were sufficiently visible (Figure 2A). The tissue was examined by confocal microscopy, and images were taken with a digital camera (C1si; Nikon, Tokyo, Japan). Yellow signals (515/530 nm) were acquired from each sample using 488 nm excitation. Fluorescence projection images of somata and dendritic fields were acquired with a 60 × oil-immersion lens. We selected 5–10 cells for each rat, and 1–5 horizontally projecting dendrites from each cell. We then measured the density and size of spines on the basal dendrite, 50–100 μm distal to the cell body (Figure 2B). Images of the spines in each dendrite were acquired with a 60 × oil-immersion lens (5.0 zoom factor; 0.0064 μm2/pixel resolution) at 0.25-μm focal steps. Image stacks were three-dimensional (3D)-deconvoluted using NIS-Elements software (Nikon) and volume rendered as 2D images to facilitate overview of the figures (Figure 2C). In total, we measured 9415 spines from 202 neurons in 33 motor cortices. Each spine was manually traced. The average number of spines per 10 μm of linear dendritic length was expressed as the spine density. All spines were drawn and no distinction was made between different spine types. We measured the cross-sectional area of the spine head in 2D reconstructed images. Image analysis was performed using Image J (National Institutes of Health, Bethesda, MD, USA). For analyses, we selected intracellularly injected cells (Control: 54 cells; PD model: 50 cells; LID model: 49 cells; LTC model: 49 cells) based on our previous criteria (Table 1; Ueno et al., ).
Figure 2
Table 1
| Rat | Cell | Analyzed basal dendrite | Analyzed spine | |
|---|---|---|---|---|
| Control | 9 | 54 | 162 | 2,320 |
| Parkinsonian | 8 | 50 | 152 | 2,107 |
| Dyskinesia | 8 | 49 | 153 | 2,419 |
| Levodopa treated control | 8 | 49 | 152 | 2,569 |
Number of rat, cell, basal dendrite, and spines analyzed.
Statistics
We analyzed the spine density and the average cross-sectional area of the spine heads in each basal dendrite. Statistical analyses were performed with EZR freeware v.1.32 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (Kanda, ). A probability level of 5% (P < 0.05) was considered statistically significant. Data are presented as means ± standard error or boxplots showing medians, and 25 and 75% quartile ranges. The spine density, cross-sectional area of the spine heads, and AIM scores were examined using parametric tests (one-way analysis of variance followed by Tukey–Kramer post-hoc test), as the Shapiro–Wilk test indicated that the distributions were normal.
Results
AIM scores in LID and LTC models
Dopaminergic denervation plus levodopa treatment (LID group) significantly increased AIM scores at day 4 (P < 0.001 cf. day 1) and day 11 (P < 0.001 cf. day 4), whereas levodopa treatment had no effect on AIM scores in control rats (LTC group) (Figure 3).
Figure 3
Morphological changes in dendritic spines of PT neurons
Forty-five animals underwent histological examinations with 12 excluded due to unsatisfactory histology. We analyzed the spine density and average cross-sectional area of spine heads in 619 basal dendrites (control = 162, PD = 152, LID = 153, LTC = 152) (Table 1; Figure 4). Using histograms from 9,415 cross-sectional areas of spine heads, the LID group showed significantly enlarged spine heads compared with the other groups (P < 0.001) (Figure 5A).
Figure 4

Representative confocal microscopy images of dendritic spines on PT neurons. Scale bar = 5 μm.
Figure 5

Morphological evaluation of spines on basal dendrites. (A) Histograms of cross-sectional areas of the analyzed spine heads. The red, green, blue, and light blue bars indicate control, PD, LID, and LTC groups, respectively. The histogram shows that the cross-sectional area of the spine heads was increased in the LID group compared with the other groups. (B) Spine density was significantly increased in the LID and LTC groups compared with the Control and PD groups. (C) Spine size was significantly increased in the LID group (*P < 0.05, **P < 0.001, one-way analysis of variance followed by post-hoc Tukey–Kramer test). C, control.
Levodopa treatment of the dopaminergic denervation (LID group) and control rats (LTC group) significantly increased the spine density of M1 PT neurons compared with the Control (P < 0.05 cf. LID; P < 0.001 cf. LTC) and PD groups (P < 0.001 cf. LID; P < 0.001 cf. LTC) (Control group: 7.2 ± 0.15/10 μm; PD group: 7.0 ± 0.20/10 μm; LID group: 7.9 ± 0.20/10 μm; LTC group: 8.5 ± 0.17/10 μm). However, dopaminergic denervation (PD group) had no effect on spine density of PT neurons compared with the Control group. No significant differences were observed between the LID group and the LTC group (Figures 4, 5B).
Dopaminergic denervation (PD group) had no effect on the spine size of PT neurons, while dopaminergic denervation plus levodopa treatment (LID group) significantly enlarged dendritic spines compared with the Control group, the PD group, and the LTC group (P < 0.001) (Figures 4, 5C). However, levodopa treatment of control rats (LTC group) had no effects on spine size (Control group: 0.14 ± 0.003 μm2; PD group: 0.14 ± 0.003 μm2; LID group: 0.16 ± 0.003 μm2; LTC group: 0.14 ± 0.002 μm2) (Figures 4, 5C).
Discussion
In this study, we demonstrated that chronic levodopa treatment in normal and LID model rats increases the spine density of PT neurons in the M1. The dendritic spines of M1 PT neurons became enlarged in the LID model, and this enlargement of spines appears to be relevant to the development of AIMs. This structural change suggests that PT neurons become supersensitive to glutamatergic inputs in dyskinetic rats.
Effect of dopaminergic denervation on dendritic spines of M1 PT neurons
We found that dopaminergic denervation alone had no effect on M1 PT neuron spine density or size (Figures 4, 5B,C). The preservation of spine density in the motor cortex after dopaminergic denervation is comparable with previous studies (Miklyaeva et al.,
There were also differences between these studies in the timing of measurements after dopaminergic lesioning (Miklyaeva et al.,
Increased spine density of M1 PT neurons with chronic levodopa treatment with or without dopaminergic denervation
Here we showed that chronic levodopa treatment with or without dopaminergic denervation increases the spine density of PT neurons in M1 (Figures 4, 5B). Levodopa normalizes the increase in spine turnover in the M1 following dopaminergic denervation (Guo et al.,
Enlargement of dendritic spines of M1 PT neurons of LID model rats
Dopaminergic denervation or levodopa treatment alone had no effect on dendritic spine size (Figures 4, 5C). However, levodopa treatment after dopaminergic denervation enlarged dendritic spines in PT neurons, with the appearance of dyskinetic movements (Figures 3, 4, 5C). Thus, chronic levodopa treatment after dopaminergic denervation results in the enlargement of dendritic spines in both IT (Ueno et al.,
We previously reported that dendritic spines become enlarged in both dSPNs in the striatum and IT neurons in the M1 cortex of the same LID model (Nishijima et al.,
Although, we did not measure the synaptic function of PT neurons using electrophysiology in this study, the spine enlargement of PT neurons probably results in supersensitivity of PT neurons to glutamatergic input in the M1 (Ueno et al.,
Conclusions
In the primary motor cortex, chronic levodopa treatment modifies the formation of dendritic spines in PT neurons with or without dopaminergic denervation. Furthermore, chronic levodopa treatment after dopaminergic denervation causes the enlargement of PT neuron dendritic spines. These results suggest that spine enlargement in PT neurons may be a key factor in the development of LID in the M1.
Funding
This study was supported by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 22590952) to MT. The funding source had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Author contributions
Conception and design of the study, data interpretation, drafting the article or revising it critically for important intellectual content, and final approval of the version to be submitted: TU, HN, SU, and MT; Data acquisition and analysis: TU.
Acknowledgments
The authors thank Ms. Saeko Osanai for study support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- 3D
3-dimensional
- 6-OHDA
6-hydroxydopamine
- AIM
abnormal involuntary movement
- dSPN
direct pathway striatal projection neurons
- iSPN
indirect pathway striatal projection neurons
- IT
intratelencephalic
- LID
levodopa-induced dyskinesia
- LTC
levodopa-treated control
- LTP
long-term potentiation
- M1
primary motor cortex
- PD
Parkinson's disease
- PT
pyramidal tract.
Abbreviations
References
1
CenciM. A.LundbladM. (2007). Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. Chapter 9:Unit 9.25. 10.1002/0471142301.ns0925s41
2
DembrowN.JohnstonD. (2014). Subcircuit-specific neuromodulation in the prefrontal cortex. Front. Neural Circuits8:54. 10.3389/fncir.2014.00054
3
DengY.LanciegoJ.Kerkerian-Le-GoffL.CoulonP.SalinP.KachidianP.et al. (2015). Differential organization of cortical inputs to striatal projection neurons of the matrix compartment in rats. Front. Syst. Neurosci.9:51. 10.3389/fnsys.2015.00051
4
DupreK. B.CruzA. V.McCoyA. J.DelavilleC.GerberC. M.EyringK. W.et al. (2016). Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease. Neurobiol. Dis.86, 1–15. 10.1016/j.nbd.2015.11.009
5
GeeS.EllwoodI.PatelT.LuongoF.DeisserothK.SohalV. S. (2012). Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J. Neurosci.32, 4959–4971. 10.1523/JNEUROSCI.5835-11.2012
6
GibbW. R.LeesA. J. (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry51, 745–752. 10.1136/jnnp.51.6.745
7
GuoL.XiongH.KimJ. I.WuY. W.LalchandaniR. R.CuiY.et al. (2015). Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson's disease. Nat. Neurosci.18, 1299–1309. 10.1038/nn.4082
8
HaljeP.TamteM.RichterU.MohammedM.CenciM. A.PeterssonP. (2012). Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J. Neurosci.32, 16541–16551. 10.1523/JNEUROSCI.3047-12.2012
9
HarveyC. D.SvobodaK. (2007). Locally dynamic synaptic learning rules in pyramidal neuron dendrites. Nature450, 1195–1200. 10.1038/nature06416
10
HospJ. A.PekanovicA.Rioult-PedottiM. S.LuftA. R. (2011). Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. J. Neurosci.31, 2481–2487. 10.1523/JNEUROSCI.5411-10.2011
11
HuangY. Z.RothwellJ. C.LuC. S.ChuangW. L.ChenR. S. (2011). Abnormal bidirectional plasticity-like effects in Parkinson's disease. Brain134(Pt 8), 2312–2320. 10.1093/brain/awr158
12
KandaY. (2013). Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant.48, 452–458. 10.1038/bmt.2012.244
13
KasaiH.FukudaM.WatanabeS.Hayashi-TakagiA.NoguchiJ. (2010). Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci.33, 121–129. 10.1016/j.tins.2010.01.001
14
KressG. J.YamawakiN.WokosinD. L.WickershamI. R.ShepherdG. M.SurmeierD. J. (2013). Convergent cortical innervation of striatal projection neurons. Nat. Neurosci.16, 665–667. 10.1038/nn.3397
15
MaedaT.KannariK.SudaT.MatsunagaM. (1999). Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum. Brain Res.817, 185–191. 10.1016/S0006-8993(98)01248-7
16
MatsuzakiM.Ellis-DaviesG. C.NemotoT.MiyashitaY.IinoM.KasaiH. (2001). Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat. Neurosci.4, 1086–1092. 10.1038/nn736
17
MatsuzakiM.HonkuraN.Ellis-DaviesG. C.KasaiH. (2004). Structural basis of long-term potentiation in single dendritic spines. Nature429, 761–766. 10.1038/nature02617
18
MiklyaevaE. I.WhishawI. Q.KolbB. (2007). A golgi analysis of cortical pyramidal cells in the unilateral parkinson rat: absence of change in the affected hemisphere vs hypertrophy in the intact hemisphere. Restor. Neurol. Neurosci.25, 91–99.
19
Molina-LunaK.PekanovicA.RohrichS.HertlerB.Schubring-GieseM.Rioult-PedottiM. S.et al. (2009). Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS ONE4:e7082. 10.1371/journal.pone.0007082
20
MoritaK. (2014). Differential cortical activation of the striatal direct and indirect pathway cells: reconciling the anatomical and optogenetic results by using a computational method. J. Neurophysiol.112, 120–146. 10.1152/jn.00625.2013
21
MurakoshiH.YasudaR. (2012). Postsynaptic signaling during plasticity of dendritic spines. Trends Neurosci.35, 135–143. 10.1016/j.tins.2011.12.002
22
NavaillesS.BioulacB.GrossC.De DeurwaerdereP. (2011). Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis.41, 585–590. 10.1016/j.nbd.2010.11.007
23
NishijimaH.SuzukiS.KonT.FunamizuY.UenoT.HagaR.et al. (2014). Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model. Mov. Disord.29, 336–343. 10.1002/mds.25826
24
OlanowC. W.ObesoJ. A.StocchiF. (2006). Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol.5, 677–687. 10.1016/S1474-4422(06)70521-X
25
PaxinosG.WatsonC. (1998). The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press.
26
PicconiB.CentonzeD.HakanssonK.BernardiG.GreengardP.FisoneG.et al. (2003). Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci.6, 501–506. 10.1038/nn1040
27
ReinerA.HartN. M.LeiW.DengY. (2010). Corticostriatal projection neurons—dichotomous types and dichotomous functions. Front. Neuroanat.4:142. 10.3389/fnana.2010.00142
28
RenT.YangX.WuN.CaiY.LiuZ.YuanW. (2011). Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats. Neurosci. Lett.502, 117–122. 10.1016/j.neulet.2011.07.042
29
RudyJ. W. (2015). Actin dynamics and the evolution of the memory trace. Brain Res.1621, 17–28. 10.1016/j.brainres.2014.12.007
30
SegalM. (2010). Dendritic spines, synaptic plasticity and neuronal survival: activity shapes dendritic spines to enhance neuronal viability. Eur. J. Neurosci.31, 2178–2184. 10.1111/j.1460-9568.2010.07270.x
31
SeongH. J.CarterA. G. (2012). D1 receptor modulation of action potential firing in a subpopulation of layer 5 pyramidal neurons in the prefrontal cortex. J. Neurosci.32, 10516–10521. 10.1523/JNEUROSCI.1367-12.2012
32
ShenW.PlotkinJ. L.FrancardoV.KoW. K.XieZ.LiQ.et al. (2015). M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia. Neuron88, 762–773. 10.1016/j.neuron.2015.10.039
33
ShippS. (2017). The functional logic of corticostriatal connections. Brain Struct. Funct. 222, 669–706. 10.1007/s00429-016-1250-9
34
UenoT.YamadaJ.NishijimaH.AraiA.MigitaK.BabaM.et al. (2014). Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia. Neurobiol. Dis.64, 142–149. 10.1016/j.nbd.2013.12.014
35
UhlG. R.HedreenJ. C.PriceD. L. (1985). Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology35, 1215–1218. 10.1212/WNL.35.8.1215
36
WangH. D.DeutchA. Y. (2008). Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology33, 1276–1286. 10.1038/sj.npp.1301521
37
XieC. L.WangW. W.ZhangS. F.YuanM. L.CheJ. Y.GanJ.et al. (2014). Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci. Rep.4:7506. 10.1038/srep07506
38
YagishitaS.Hayashi-TakagiA.Ellis-DaviesG. C.UrakuboH.IshiiS.KasaiH. (2014). A critical time window for dopamine actions on the structural plasticity of dendritic spines. Science345, 1616–1620. 10.1126/science.1255514
39
YangX.ChenY.HongX.WuN.SongL.YuanW.et al. (2012a). Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. Drug Des. Devel. Ther.6, 341–347. 10.2147/DDDT.S38008
40
YangX.ZhengR.CaiY.LiaoM.YuanW.LiuZ. (2012b). Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int. J. Nanomed.7, 2077–2086. 10.2147/IJN.S30463
Summary
Keywords
Parkinson's disease, dyskinesia, levodopa, motor cortex, dendritic spines, plasticity, 6-hydroxydopamine, pyramidal neuron
Citation
Ueno T, Nishijima H, Ueno S and Tomiyama M (2017) Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced Dyskinesia. Front. Neurosci. 11:206. doi: 10.3389/fnins.2017.00206
Received
03 February 2017
Accepted
27 March 2017
Published
13 April 2017
Volume
11 - 2017
Edited by
Jaewon Ko, Daegu Gyeongbuk Institute of Science and Technology, South Korea
Reviewed by
Se-Young Choi, Seoul National University, South Korea; Weien Yuan, Shanghai Jiao Tong University, China
Updates

Check for updates
Copyright
© 2017 Ueno, Nishijima, Ueno and Tomiyama.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tatsuya Ueno lacote19thg@gmail.com
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.